The information was submitted to the public on January 25, 2018 at 8:20 CET
CellaVision AB (publ) will publish the year-end bulletin on February 7, 2019 at 8:20 CET. The report will be available at www.cellavision.com (http://www.cellavision.com/)
In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CET where Zlatko Rihter, CEO, will present and comment the report.
The presentation will be in English via a conference call or audio webcast:
https://tv.streamfabriken.com/cellavision-q4-2018
Phone number for the conference:
SE: +46 8 505 583 55
UK: +44 333 300 9263
US: +1 646 722 4956
About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the market support organizations in the US, Canada, China, Sweden, Japan, UAE, Korea, Australia, France, Germany, Brazil, Great Britain, Mexico, India and Thailand. In 2017 sales were SEK 309 million and the company's growth target is 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list.
Read more at www.cellavision.com (http://www.cellavision.com/)
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellaVision AB via Globenewswire
